Cargando…

Apolipoprotein M—A Marker or an Active Player in Type II Diabetes?

Apolipoprotein M (apoM) is a member of the lipocalin superfamily and an important carrier of the small bioactive lipid sphingosine-1-phosphate (S1P). The apoM/S1P complex is attached to all lipoproteins, but exhibits a significant preference for high-density lipoproteins. Although apoM, S1P, and the...

Descripción completa

Detalles Bibliográficos
Autor principal: Christoffersen, Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176018/
https://www.ncbi.nlm.nih.gov/pubmed/34093440
http://dx.doi.org/10.3389/fendo.2021.665393
_version_ 1783703171234791424
author Christoffersen, Christina
author_facet Christoffersen, Christina
author_sort Christoffersen, Christina
collection PubMed
description Apolipoprotein M (apoM) is a member of the lipocalin superfamily and an important carrier of the small bioactive lipid sphingosine-1-phosphate (S1P). The apoM/S1P complex is attached to all lipoproteins, but exhibits a significant preference for high-density lipoproteins. Although apoM, S1P, and the apoM/S1P complex have been discovered more than a decade earlier, the overall function of the apoM/S1P complex remains controversial. Evidence suggests that the complex plays a role in inflammation and cholesterol metabolism and is important for maintaining a healthy endothelial barrier, regulating the turnover of triglycerides from lipoproteins, and reducing cholesterol accumulation in vessel walls. Recent studies have also addressed the role of apoM and S1P in the development of diabetes and obesity. However, limited evidence is available, and the data published so far deviates. This review discusses the specific elements indicative of the protective or harmful effects of apoM, S1P, and the apoM/S1P complex on type 2 diabetes development. Since drugs targeting the S1P system and its receptors are available and could be potentially used for treating diabetes, this research topic is a pertinent one.
format Online
Article
Text
id pubmed-8176018
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81760182021-06-05 Apolipoprotein M—A Marker or an Active Player in Type II Diabetes? Christoffersen, Christina Front Endocrinol (Lausanne) Endocrinology Apolipoprotein M (apoM) is a member of the lipocalin superfamily and an important carrier of the small bioactive lipid sphingosine-1-phosphate (S1P). The apoM/S1P complex is attached to all lipoproteins, but exhibits a significant preference for high-density lipoproteins. Although apoM, S1P, and the apoM/S1P complex have been discovered more than a decade earlier, the overall function of the apoM/S1P complex remains controversial. Evidence suggests that the complex plays a role in inflammation and cholesterol metabolism and is important for maintaining a healthy endothelial barrier, regulating the turnover of triglycerides from lipoproteins, and reducing cholesterol accumulation in vessel walls. Recent studies have also addressed the role of apoM and S1P in the development of diabetes and obesity. However, limited evidence is available, and the data published so far deviates. This review discusses the specific elements indicative of the protective or harmful effects of apoM, S1P, and the apoM/S1P complex on type 2 diabetes development. Since drugs targeting the S1P system and its receptors are available and could be potentially used for treating diabetes, this research topic is a pertinent one. Frontiers Media S.A. 2021-05-21 /pmc/articles/PMC8176018/ /pubmed/34093440 http://dx.doi.org/10.3389/fendo.2021.665393 Text en Copyright © 2021 Christoffersen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Christoffersen, Christina
Apolipoprotein M—A Marker or an Active Player in Type II Diabetes?
title Apolipoprotein M—A Marker or an Active Player in Type II Diabetes?
title_full Apolipoprotein M—A Marker or an Active Player in Type II Diabetes?
title_fullStr Apolipoprotein M—A Marker or an Active Player in Type II Diabetes?
title_full_unstemmed Apolipoprotein M—A Marker or an Active Player in Type II Diabetes?
title_short Apolipoprotein M—A Marker or an Active Player in Type II Diabetes?
title_sort apolipoprotein m—a marker or an active player in type ii diabetes?
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176018/
https://www.ncbi.nlm.nih.gov/pubmed/34093440
http://dx.doi.org/10.3389/fendo.2021.665393
work_keys_str_mv AT christoffersenchristina apolipoproteinmamarkeroranactiveplayerintypeiidiabetes